Unknown

Dataset Information

0

Safety and immunologic effects of IL-15 administration in nonhuman primates.


ABSTRACT: The administration of cytokines that modulate endogenous or transferred T-cell immunity could improve current approaches to clinical immunotherapy. Interleukin-2 (IL-2) is used most commonly for this purpose, but causes systemic toxicity and preferentially drives the expansion of CD4(+)CD25(+)Foxp3(+) regulatory T cells, which can inhibit antitumor immunity. IL-15 belongs to the gamma(c) cytokine family and possesses similar properties to IL-2, including the ability to induce T-cell proliferation. Whereas IL-2 promotes apoptosis and limits the survival of CD8(+) memory T cells, IL-15 is required for the establishment and maintenance of CD8(+) T-cell memory. However, limited data are available to guide the clinical use of IL-15. Here, we demonstrate in nonhuman primates that IL-15 administration expands memory CD8(+) and CD4(+) T cells, and natural killer (NK) cells in the peripheral blood, with minimal increases in CD4(+)CD25(+)Foxp3(+) regulatory T cells. Daily administration of IL-15 resulted in persistently elevated plasma IL-15 levels and transient toxicity. Intermittent administration of IL-15 allowed clearance of IL-15 between doses and was safe for more than 3 weeks. These findings demonstrate that IL-15 has profound immunomodulatory properties distinct from those described for IL-2, and suggest that intermittent administration of IL-15 should be considered in clinical studies.

SUBMITTER: Berger C 

PROVIDER: S-EPMC2746471 | biostudies-literature | 2009 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Safety and immunologic effects of IL-15 administration in nonhuman primates.

Berger Carolina C   Berger Michael M   Hackman Robert C RC   Gough Michael M   Elliott Carole C   Jensen Michael C MC   Riddell Stanley R SR  

Blood 20090715 12


The administration of cytokines that modulate endogenous or transferred T-cell immunity could improve current approaches to clinical immunotherapy. Interleukin-2 (IL-2) is used most commonly for this purpose, but causes systemic toxicity and preferentially drives the expansion of CD4(+)CD25(+)Foxp3(+) regulatory T cells, which can inhibit antitumor immunity. IL-15 belongs to the gamma(c) cytokine family and possesses similar properties to IL-2, including the ability to induce T-cell proliferatio  ...[more]

Similar Datasets

| S-EPMC2995354 | biostudies-literature
| S-EPMC1459071 | biostudies-literature
| S-EPMC7466740 | biostudies-literature
| S-EPMC5483994 | biostudies-literature
| S-EPMC3370077 | biostudies-literature
| S-EPMC10651209 | biostudies-literature
| S-EPMC5057154 | biostudies-literature
| S-EPMC3380299 | biostudies-literature
| S-EPMC4047998 | biostudies-literature
| S-EPMC7184633 | biostudies-literature